Canaccord lowered the firm’s price target on GH Research to $30 from $35 and keeps a Buy rating on the shares. The firm said they tweaked their probability of approval of GH001 in TRD down from 45% to 40% and still assume a potential launch in US/Europe in 2028E, but at a somewhat later time in the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GHRS:
- GH Research price target lowered to $40 from $45 at H.C. Wainwright
- GH Research reports Q3 EPS (11c), consensus (20c)
- GH Research Reports Third Quarter Financial Results and Provides Business Updates
- Eight new option listings on October 4th
- GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
